Pure recombinant enzyme
Related Products
Measurement and Detection Target(s)
27533Fatty Acid Desaturase 1 Monoclonal Antibody (Clone 3A10.1)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Fatty Acid Desaturase 1 (human recombinant)

Item No. 25827

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • Acyl-CoA (8-3)-Desaturase, Δ5 Desaturase
  • Δ5D
  • Δ5 Desaturase
  • EC 1.14.19.
  • FADS1
  • FADSΔ5
  • FADS6
  • Δ5 Fatty Acid Desaturase
  • Linoleoyl-CoA Desaturase (Δ6 Desaturase)-Like 1
  • TU12
Purity
≥80% estimated by SDS-PAGE
Source
Recombinant N-terminal His-tagged FADS1 N-terminal domain purified from E. coli
Amino Acids
2-121
MW
15.89 kDa
Formulation (Request formulation change)
50 mM HEPES, pH 8.0, with 150 mM sodium chloride and 10% glycerol
UniProt Accession №
O60427
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 µg

    $528

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Fatty acid desaturase 1 (FADS1), also known as Δ5 desaturase, is a 444-amino acid transmembrane protein encoded by FADS1.1 This product is the N-terminal cytoplasmic domain of FADS1, corresponding to residues 2-121 of the full-length sequence. It catalyzes conversion of dihomo-γ-linolenic acid (Item No. 90230) to arachidonic acid (Item No. 90010) and ω-3 arachidonic acid (Item No. 90011) to eicosapentaenoic acid (Item Nos. 90110 | 90110.1 | 21908) during the production of ω-6 and ω-3 long-chain polyunsaturated fatty acids (LC-PUFAs), respectively. Hepatic FADS1 protein levels and mRNA expression are increased in mice with high-fat diet-induced obesity and non-alcoholic steatohepatitis (NASH).2 Tissue-selective knockdown of fads1 in the liver, adipose tissue, and reticuloendothelial system of adult hyperlipidemic LDL receptor-null mice promotes hepatic inflammation and formation of atherosclerotic plaques and suppresses hepatic lipogenesis.3 Increased expression of FADS1 positively correlates with disease-free survival and overall survival times in patients with esophageal squamous cell carcinoma (ESCC).4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Lattka, E., Illig, T., Heinrich, J., et al. FADS gene cluster polymorphisms: Important modulators of fatty acid levels and their impact on atopic diseases. J. Nutrigenet. Nutrigenomics 2(3), 119-128 (2009).

    2. López-Vicario, C., González-Périz, A., Rius, B., et al. Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut 63(2), 344-355 (2014).

    3. Gromovsky, A.D., Schugar, R.C., Brown, A.L., et al. The Δ-5 fatty acid desaturase FADS1 impacts metabolic disease by balancing pro-inflammatory and pro-resolving lipid mediators. Arterisoscler. Thromb. Vasc. Biol. 38(1), 218-231 (2018).

    4. Du, Y., Yan, S.M., Gu, W.Y., et al. Decreased expression of FADS1 predicts a poor prognosis in patients with esophageal squamous cell carcinoma. Asian Pac. J. Cancer Prev. 16(12), 5089-5094 (2015).